4D Molecular Therapeutics appoints Ashoo Gupta as Principal Financial Officer

4D Molecular Therapeutics, Inc.

Ashoo Gupta appointed Principal Financial Officer and Principal Accounting Officer effective September 30, 2025.
Mr. Gupta previously served as VP Finance & Controller at 4D since June 2024.
Prior roles include VP Finance and Corporate Controller at Kyverna Therapeutics and Executive Director of Accounting at Myovant Sciences.
Board amended and restated bylaws to update advance notice procedures for business and director nominations.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

4D Molecular Therapeutics, Inc.: Board amended and restated Bylaws to update advance notice procedures for business brought before a meeting and for nominations of directors (effective 2025-09-30).

Change: bylaw amendment
Effective: 2025-09-30

Exact text from the filing

On September 30, 2025, the Board amended and restated the Company’s current amended and restated bylaws (the “Amended and Restated Bylaws”). The Amended and Restated Bylaws were amended to, among other revisions, update the advance notice procedures for business brought before a meeting and update the advance notice procedures for nominations of directors.

View on SEC.gov

262 governance changes filed in the last 30 days. Browse all governance changes →

4D Molecular Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-228289

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.